John Temperato

This profile gathers the share dealings of John Temperato in 9 Meters Biopharma, Inc., where the filings describe the role as chief executive. Over a trading history stretching from 15 June 2020 to 27 March 2023, the count stands at 15 filings.

Purchases make up the whole of the open-market record (10 purchases, €398k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants.

A typical purchase (the median) is worth €34k. Clusters matter here: 5 out of 10 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 29 March 2023 came the latest disclosure, a share grant in 9 Meters Biopharma, Inc. The last purchase on record was published on 8 July 2022, which is 1,569 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.